Another report demonstrated that IFN-β gene therapy mediated by an intracranial adenoviral vector significantly reduced the tumor burden and doubled the median survival in highly migratory GBM in a syngeneic mouse model [54]. This evidence concerns the gene IFNB1 and glioblastoma.